Shares of Regeneron Pharmaceuticals Inc. slid 3.61% to $665.46 Tuesday, on what proved to be an all-around favorable trading ...
NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and ...
Guggenheim lowered the firm’s price target on Regeneron (REGN) to $950 from $1,200 and keeps a Buy rating on the shares. The firm, which is ...
Regeneron, which is seeking FDA approval of linvoseltamab for adults with relapsed/refractory multiple myeloma that has progressed after at least three prior therapies, said the agency set a new ...
Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...
GlobalData on MSN1d
Regeneron’s macular oedema therapy shows promise in Phase III trialIn the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.
Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...
Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...
Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...
News of a significant earnings beat propelled Regeneron Pharmaceuticals (NASDAQ: REGN) to a nearly 5% share price gain on the ...
The PDUFA action date for an FDA decision for linvoseltamab to treat adult patients with relapsed/refractory multiple myeloma ...
This was the stock's second consecutive day of losses.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback